Jon Travers
Overview
Explore the profile of Jon Travers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
579
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vora S, Chatterjee S, Andrew A, Kumar R, Proctor M, Zeng Z, et al.
Cell Death Dis
. 2025 Jan;
16(1):7.
PMID: 39779678
Polyploidy is a common outcome of chemotherapies, but there is conflicting evidence as to whether polyploidy is an adverse, benign or even favourable outcome. We show Aurora B kinase inhibitors...
2.
Vora S, Andrew A, Kumar R, Nazareth D, Bonfim-Melo A, Lim Y, et al.
Cell Death Dis
. 2024 Nov;
15(11):810.
PMID: 39521795
Aurora B kinase (AURKB) inhibitors have been trialled in a range of different tumour types but are not approved for any indication. Expression of the human papilloma virus (HPV) oncogenes...
3.
Bertran-Alamillo J, Gimenez-Capitan A, Roman R, Talbot S, Whiteley R, Floch N, et al.
Mol Cancer
. 2023 Jul;
22(1):110.
PMID: 37443114
Background: Drugs targeting the spindle assembly checkpoint (SAC), such as inhibitors of Aurora kinase B (AURKB) and dual specific protein kinase TTK, are in different stages of clinical development. However,...
4.
Ramkumar K, Tanimoto A, Della Corte C, Stewart C, Wang Q, Shen L, et al.
Clin Cancer Res
. 2023 Jun;
29(16):3237-3249.
PMID: 37289191
Purpose: Therapeutic resistance to frontline therapy develops rapidly in small cell lung cancer (SCLC). Treatment options are also limited by the lack of targetable driver mutations. Therefore, there is an...
5.
Chou D, Furlong B, Posey R, Kyprianou C, OSullivan L, David R, et al.
Nat Commun
. 2022 Oct;
13(1):6021.
PMID: 36224199
Drug-induced cytopenias are a prevalent and significant issue that worsens clinical outcomes and hinders the effective treatment of cancer. While reductions in blood cell numbers are classically associated with traditional...
6.
McCoull W, Boyd S, Brown M, Coen M, Collingwood O, Davies N, et al.
J Med Chem
. 2021 Sep;
64(18):13524-13539.
PMID: 34478292
Inhibition of Mer and Axl kinases has been implicated as a potential way to improve the efficacy of current immuno-oncology therapeutics by restoring the innate immune response in the tumor...
7.
Harper J, Burke S, Travers J, Rath N, Leinster A, Navarro C, et al.
Mol Cancer Ther
. 2021 Jul;
20(9):1723-1734.
PMID: 34224361
A recombinant Newcastle Disease Virus (NDV), encoding either a human (NDVhuGM-CSF, MEDI5395) or murine (NDVmuGM-CSF) GM-CSF transgene, combined broad oncolytic activity with the ability to significantly modulate genes related to...
8.
Gerdes H, Casado P, Dokal A, Hijazi M, Akhtar N, Osuntola R, et al.
Nat Commun
. 2021 Mar;
12(1):1850.
PMID: 33767176
Artificial intelligence and machine learning (ML) promise to transform cancer therapies by accurately predicting the most appropriate therapies to treat individual patients. Here, we present an approach, named Drug Ranking...
9.
Nilsson M, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J, et al.
Sci Transl Med
. 2020 Sep;
12(559).
PMID: 32878980
Acquired resistance to tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) remains a clinical challenge. Especially challenging are cases in which resistance emerges through EGFR-independent mechanisms, such as...
10.
Ghosh S, Sharma G, Travers J, Kumar S, Choi J, Jun H, et al.
Mol Cancer Ther
. 2018 Dec;
18(3):632-641.
PMID: 30587557
Progressive upregulation of checkpoints on tumor-infiltrating lymphocytes promotes an immunosuppressive tumor microenvironment, severely compromising tumor immunity. Lymphocyte activation gene-3 (LAG-3) is a coinhibitory receptor associated with impaired T-cell function and...